BOC 2026 | Prof. Xinan Sheng: RC48-C016 Redefines First-Line Treatment for Advanced Urothelial Carcinoma, While Sequential ADC Strategies Open New Horizons in Later-Line Therapy

BOC 2026 | Prof. Xinan Sheng: RC48-C016 Redefines First-Line Treatment for Advanced Urothelial Carcinoma, While Sequential ADC Strategies Open New Horizons in Later-Line Therapy

With the rapid evolution of antibody-drug conjugates (ADCs) and immunotherapy, the treatment paradigm for urothelial carcinoma (UC) is undergoing profound transformation. During the recent China Clinical Oncology Annual Advances Symposium (BOC) and Best of CSCO 2026 China, leading oncology experts gathered to discuss the latest international advances and their translation into clinical practice.
Pujiang Prostate Cancer Conference | Prof. Xiaojie Bian: Translating the Latest ASCO Advances into Precision Prostate Cancer Care and Driving Innovation in China

Pujiang Prostate Cancer Conference | Prof. Xiaojie Bian: Translating the Latest ASCO Advances into Precision Prostate Cancer Care and Driving Innovation in China

As one of China's premier academic meetings in genitourinary oncology, the Pujiang Prostate Cancer Conference continues to serve as an important platform for integrating international advances with domestic clinical practice. This year's meeting featured a dedicated multidisciplinary session, bringing together leading Chinese experts to discuss emerging directions in prostate cancer management.
Pujiang Prostate Cancer Conference | Prof. Guowen Lin: Three Key Assessment Dimensions for Selecting Candidates for Salvage Prostatectomy and New Surgical Strategies for Recurrence After Focal Ablation

Pujiang Prostate Cancer Conference | Prof. Guowen Lin: Three Key Assessment Dimensions for Selecting Candidates for Salvage Prostatectomy and New Surgical Strategies for Recurrence After Focal Ablation

The Pujiang Prostate Cancer Conference was held in Shanghai on June 26–27, 2026. Organized by the Shanghai Anti-Cancer Association and its Genitourinary Oncology Committee, and hosted by Fudan University Shanghai Cancer Center, the meeting focused on major clinical issues including salvage surgery following prostate cancer recurrence and the integration of multiple local treatment modalities.
Pujiang Prostate Cancer Conference | Prof. Yao Zhu: The Clinical Significance of the APCCC Consensus—Bridging Clinical Guidelines and Real-World Practice

Pujiang Prostate Cancer Conference | Prof. Yao Zhu: The Clinical Significance of the APCCC Consensus—Bridging Clinical Guidelines and Real-World Practice

The 2026 Pujiang Prostate Cancer Conference was held in Shanghai on June 26–27, 2026, under the theme "Standardization, Precision, Chinese Innovation, and Global Collaboration." The conference featured in-depth discussions on key topics including early prostate cancer screening and precision diagnosis, optimization of local treatment strategies, innovation in advanced disease management, and the development of comprehensive care throughout the disease course.
BOC Spotlight on Precision HER2 Therapy | Disitamab Vedotin Sets a New Benchmark for China’s Homegrown Innovation

BOC Spotlight on Precision HER2 Therapy | Disitamab Vedotin Sets a New Benchmark for China’s Homegrown Innovation

In recent years, the treatment landscape for urothelial carcinoma (UC) has entered the era of precision medicine, with emerging therapeutic strategies offering new hope for patients. At the recent China Clinical Oncology Annual Advances Symposium (BOC) and Best of CSCO 2026 China, experts highlighted China's most significant original oncology achievements of the year and reviewed major advances in precision oncology across multiple tumor types, including genitourinary cancers, further advancing standardized cancer care in China.
Pujiang Prostate Cancer Conference | Prof. Yong Yang: The Predictive Value of Deep PSA Response and Treatment Optimization in mHSPC

Pujiang Prostate Cancer Conference | Prof. Yong Yang: The Predictive Value of Deep PSA Response and Treatment Optimization in mHSPC

The 2026 Pujiang Prostate Cancer Conference was held in Shanghai on June 26–27, 2026, under the theme "Standardization, Precision, Chinese Innovation, and Global Collaboration." The meeting brought together leading experts in uro-oncology from across China to showcase advances in standardized prostate cancer management and cutting-edge research.
ASCO China Voice | Professors Claudio Vernieri & Man Li: PALMARES-2 Highlights the Potential of CDK4/6 Inhibitor Beyond Progression and Combined Local Therapy

ASCO China Voice | Professors Claudio Vernieri & Man Li: PALMARES-2 Highlights the Potential of CDK4/6 Inhibitor Beyond Progression and Combined Local Therapy

At the 2026 ASCO Annual Meeting, Professor Claudio Vernieri from the Fondazione IRCCS Istituto Nazionale dei Tumori (Italy) presented the key findings of the PALMARES-2 study. Among patients with HR+/HER2− metastatic breast cancer, only about 20% continued first-line endocrine therapy (ET) plus a CDK4/6 inhibitor beyond first progression, achieving a median real-world progression-free survival (rwPFS) of 10.5 months and a median real-world overall survival (rwOS) of 71.3 months. The study also suggested that adding local treatment—particularly radiotherapy—was associated with improved outcomes.
Rethinking the Limits of Flexible Ureteroscopy — An Interview with Prof. John D. Denstedt

Rethinking the Limits of Flexible Ureteroscopy — An Interview with Prof. John D. Denstedt

As the prevalence of kidney stones continues to rise and complex stone disease becomes increasingly common, there is growing demand for minimally invasive, effective, and safe treatment strategies. Flexible ureteroscopy has become a cornerstone of upper urinary tract stone management; however, its role in treating large stone burdens, infection-related stones, and anatomically complex cases remains a subject of debate. Meanwhile, advances such as laser lithotripsy, single-use ureteroscopes, and suction-assisted access sheaths continue to expand treatment possibilities. Balancing maximal stone clearance with minimal complications remains one of the key challenges in modern endourology.